EyePoint (EYPT) Net Equity Issued and Repurchased (2011 - 2026)
EyePoint (EYPT) posted Net Equity Issued and Repurchased of $166.8 million for Q4 2025, up 2317.2% sequentially from $6.9 million in Q3 2025, and up 10.08% YoY from $151.5 million in Q4 2024.
Analysis
EyePoint (EYPT) Net Equity Issued and Repurchased (2011 - 2026) Analysis & Trends
EyePoint has reported Net Equity Issued and Repurchased for 13 years, with the latest figure at $166.8 million in Q4 2025.
- Quarterly Net Equity Issued and Repurchased rose 10.08% year-over-year to $166.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $337.4 million (down 14.3% YoY) and the FY2025 annual result came in at $173.4 million, up 6.2% from the prior year.
- Net Equity Issued and Repurchased grew to $166.8 million in Q4 2025 per EYPT's latest filing, from $6.9 million in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $230.0 million in Q4 2023 and troughed at -$7.3 million in Q3 2021.
- A 4-year average of $84.5 million and a median of $63.9 million in 2021 frame the typical range for Net Equity Issued and Repurchased.
- The widest YoY moves for Net Equity Issued and Repurchased: up 470.21% in 2021, down 252.06% in 2021.
- Over 4 years, Net Equity Issued and Repurchased stood at -$7.3 million in 2021, then jumped by 3243.36% to $230.0 million in 2023, then sank by 34.12% to $151.5 million in 2024, then climbed by 10.08% to $166.8 million in 2025.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $166.8 million, $6.9 million, and $151.5 million for Q4 2025, Q3 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | 20.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 20.20 Mn |
| Dec 31, 2025 | 166.79 Mn |
| Sep 30, 2025 | 6.90 Mn |
| Dec 31, 2024 | 151.52 Mn |
| Sep 30, 2024 | 12.20 Mn |
| Dec 31, 2023 | 230.00 Mn |
| Sep 30, 2021 | -7.32 Mn |
| Jun 30, 2021 | -1,000.00 |
| Mar 31, 2021 | 115.67 Mn |
| Dec 31, 2020 | 25.12 Mn |
| Sep 30, 2020 | 4.81 Mn |
| Jun 30, 2020 | -295,000.00 |
| Mar 31, 2020 | 20.29 Mn |
| Dec 31, 2019 | 1.87 Mn |
| Sep 30, 2019 | 2.41 Mn |
| Jun 30, 2019 | 43,000.00 |
| Sep 30, 2018 | 34.47 Mn |
| Jun 30, 2018 | 34.47 Mn |
| Mar 31, 2018 | 9.27 Mn |
| Dec 31, 2017 | -27.43 Mn |